Neurofibromatosis as a gateway to better treatment for a variety of malignancies

Annette C. Bakker, Salvatore La Rosa, Lawrence (Larry) Sherman, Pamela Knight, Hyerim Lee, Patrice Pancza, Marco Nievo

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    The neurofibromatoses (NF) are a group of rare genetic disorders that can affect all races equally at an incidence from 1:3000 (NF1) to a log unit lower for NF2 and schwannomatosis. Since the research community is reporting an increasing number of malignant cancers that carry mutations in the NF genes, the general interest of both the research and pharma community is increasing and the authors saw an opportunity to present a novel, fresh approach to drug discovery in NF.The aim of the paper is to challenge the current drug discovery approach to NF, whereby existing targeted therapies that are either in the clinic or on the market for other disease indications are repurposed for NF. We offer a suggestion for an alternative drug discovery approach. In the new approach, selective and tolerable targeted therapies would be developed for NF and later expanded to patients with more complex diseases such as malignant cancer in which the NF downstream pathways are deregulated.The Children's Tumor Foundation, together with some other major NF funders, is playing a key role in funding critical initiatives that will accelerate the development of better targeted therapies for NF patients, while these novel, innovative treatments could potentially be beneficial to molecularly characterized cancer patients in which NF mutations have been identified.

    Original languageEnglish (US)
    JournalProgress in Neurobiology
    DOIs
    StateAccepted/In press - Jul 27 2015

    Fingerprint

    Neurofibromatoses
    Neoplasms
    Drug Discovery
    Therapeutics
    Mutation
    Inborn Genetic Diseases
    Research

    Keywords

    • Children's Tumor Foundation
    • Drug discovery
    • Neurofibromatosis 1
    • Neurofibromatosis 2
    • NF1
    • NF2
    • Review
    • Schwannomatosis

    ASJC Scopus subject areas

    • Neuroscience(all)

    Cite this

    Neurofibromatosis as a gateway to better treatment for a variety of malignancies. / Bakker, Annette C.; La Rosa, Salvatore; Sherman, Lawrence (Larry); Knight, Pamela; Lee, Hyerim; Pancza, Patrice; Nievo, Marco.

    In: Progress in Neurobiology, 27.07.2015.

    Research output: Contribution to journalArticle

    Bakker, Annette C. ; La Rosa, Salvatore ; Sherman, Lawrence (Larry) ; Knight, Pamela ; Lee, Hyerim ; Pancza, Patrice ; Nievo, Marco. / Neurofibromatosis as a gateway to better treatment for a variety of malignancies. In: Progress in Neurobiology. 2015.
    @article{6bcebbd9a92a47d09373b248fbd62b85,
    title = "Neurofibromatosis as a gateway to better treatment for a variety of malignancies",
    abstract = "The neurofibromatoses (NF) are a group of rare genetic disorders that can affect all races equally at an incidence from 1:3000 (NF1) to a log unit lower for NF2 and schwannomatosis. Since the research community is reporting an increasing number of malignant cancers that carry mutations in the NF genes, the general interest of both the research and pharma community is increasing and the authors saw an opportunity to present a novel, fresh approach to drug discovery in NF.The aim of the paper is to challenge the current drug discovery approach to NF, whereby existing targeted therapies that are either in the clinic or on the market for other disease indications are repurposed for NF. We offer a suggestion for an alternative drug discovery approach. In the new approach, selective and tolerable targeted therapies would be developed for NF and later expanded to patients with more complex diseases such as malignant cancer in which the NF downstream pathways are deregulated.The Children's Tumor Foundation, together with some other major NF funders, is playing a key role in funding critical initiatives that will accelerate the development of better targeted therapies for NF patients, while these novel, innovative treatments could potentially be beneficial to molecularly characterized cancer patients in which NF mutations have been identified.",
    keywords = "Children's Tumor Foundation, Drug discovery, Neurofibromatosis 1, Neurofibromatosis 2, NF1, NF2, Review, Schwannomatosis",
    author = "Bakker, {Annette C.} and {La Rosa}, Salvatore and Sherman, {Lawrence (Larry)} and Pamela Knight and Hyerim Lee and Patrice Pancza and Marco Nievo",
    year = "2015",
    month = "7",
    day = "27",
    doi = "10.1016/j.pneurobio.2016.01.004",
    language = "English (US)",
    journal = "Progress in Neurobiology",
    issn = "0301-0082",
    publisher = "Elsevier Limited",

    }

    TY - JOUR

    T1 - Neurofibromatosis as a gateway to better treatment for a variety of malignancies

    AU - Bakker, Annette C.

    AU - La Rosa, Salvatore

    AU - Sherman, Lawrence (Larry)

    AU - Knight, Pamela

    AU - Lee, Hyerim

    AU - Pancza, Patrice

    AU - Nievo, Marco

    PY - 2015/7/27

    Y1 - 2015/7/27

    N2 - The neurofibromatoses (NF) are a group of rare genetic disorders that can affect all races equally at an incidence from 1:3000 (NF1) to a log unit lower for NF2 and schwannomatosis. Since the research community is reporting an increasing number of malignant cancers that carry mutations in the NF genes, the general interest of both the research and pharma community is increasing and the authors saw an opportunity to present a novel, fresh approach to drug discovery in NF.The aim of the paper is to challenge the current drug discovery approach to NF, whereby existing targeted therapies that are either in the clinic or on the market for other disease indications are repurposed for NF. We offer a suggestion for an alternative drug discovery approach. In the new approach, selective and tolerable targeted therapies would be developed for NF and later expanded to patients with more complex diseases such as malignant cancer in which the NF downstream pathways are deregulated.The Children's Tumor Foundation, together with some other major NF funders, is playing a key role in funding critical initiatives that will accelerate the development of better targeted therapies for NF patients, while these novel, innovative treatments could potentially be beneficial to molecularly characterized cancer patients in which NF mutations have been identified.

    AB - The neurofibromatoses (NF) are a group of rare genetic disorders that can affect all races equally at an incidence from 1:3000 (NF1) to a log unit lower for NF2 and schwannomatosis. Since the research community is reporting an increasing number of malignant cancers that carry mutations in the NF genes, the general interest of both the research and pharma community is increasing and the authors saw an opportunity to present a novel, fresh approach to drug discovery in NF.The aim of the paper is to challenge the current drug discovery approach to NF, whereby existing targeted therapies that are either in the clinic or on the market for other disease indications are repurposed for NF. We offer a suggestion for an alternative drug discovery approach. In the new approach, selective and tolerable targeted therapies would be developed for NF and later expanded to patients with more complex diseases such as malignant cancer in which the NF downstream pathways are deregulated.The Children's Tumor Foundation, together with some other major NF funders, is playing a key role in funding critical initiatives that will accelerate the development of better targeted therapies for NF patients, while these novel, innovative treatments could potentially be beneficial to molecularly characterized cancer patients in which NF mutations have been identified.

    KW - Children's Tumor Foundation

    KW - Drug discovery

    KW - Neurofibromatosis 1

    KW - Neurofibromatosis 2

    KW - NF1

    KW - NF2

    KW - Review

    KW - Schwannomatosis

    UR - http://www.scopus.com/inward/record.url?scp=84959133679&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84959133679&partnerID=8YFLogxK

    U2 - 10.1016/j.pneurobio.2016.01.004

    DO - 10.1016/j.pneurobio.2016.01.004

    M3 - Article

    JO - Progress in Neurobiology

    JF - Progress in Neurobiology

    SN - 0301-0082

    ER -